• About Amgen
  • Science
  • Corporate Giving
  • Site Map
  • Search
  • Privacy & Terms
  • Contact Us
Amgen
  • Patients
  • Medical Professionals
  • Partners
  • Investors
  • Careers
  • Media
  • print
  • mail
  • Home
  • Medical Professionals
  • Products
  • Information on Aranesp® Phase 3 Study in Cancer Patients

  • Overview
  • Products
  • Update to U.S. Prescribing Information for Aranesp® and EPOGEN®
  • Counterfeit Drug Statement
  • Information on Aranesp® Phase 3 Study in Cancer Patients
  • PRCA Update
  • Disease / Condition Info
  • Clinical Trials
  • Resources
  • R&D Vision
  • Reimbursement Connection®
  • Medical Information
  • Pharmacy Affairs
Information on Aranesp® Phase 3 Study in Cancer Patients

Amgen Comments on Phase 3 Study in Cancer Patients with Anemia Not Due to Concurrent Chemotherapy (Feb. 2, 2007)

Letter to Oncologists on Aranesp® (Jan. 26, 2007)

For more information about study results, please visit either clinicalstudyresults.org or clinicaltrials.gov.

 

 

 

 


footer